|View printer-friendly version|
Spring Bank Announces Inarigivir Abstracts Accepted for Oral and Poster Presentations at The International Liver Congress™ (EASL 2019)
Full inarigivir (IRIG) 200mg cohort results to be presented as a late breaker oral presentation at General Session II and Award Ceremony I
Poster presentation to describe the antiviral activity of IRIG in HBV clinical isolates consisting of nucleoside/CpAM-resistant variants
The late-breaker oral presentation by Professor
Additional details, including presentation abstracts, can be found on the ILC website at https://ilc-congress.eu/. A copy of the presentation materials will be accessible by visiting the Presentations and Publications section of the
Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether results obtained in preclinical studies and clinical trials will be indicative of results obtained in future clinical trials; whether preliminary data reported by
In addition, the forward-looking statements included in this press release represent Spring Bank’s views as of the date hereof.
Source: Spring Bank Pharmaceuticals, Inc.